Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)

This study has been completed.
Sponsor:
Collaborator:
Kuopio University Hospital
Information provided by (Responsible Party):
Laurantis Pharma, Ltd.
ClinicalTrials.gov Identifier:
NCT01476332
First received: November 10, 2011
Last updated: May 15, 2012
Last verified: May 2012

November 10, 2011
May 15, 2012
November 2011
March 2012   (final data collection date for primary outcome measure)
IER (Institute of Eye Research) grading scale evaluates bulbar conjunctival redness, lid redness and corneal staining and extent [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01476332 on ClinicalTrials.gov Archive Site
  • Ocular comfort rating [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • Early Treatment Diabetic Retinopathy Study table, a visual acuity test [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • Anterior chamber cells and flare using SUN Working Group Grading Schemes [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • Ocular pressure [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • Schirmer's test [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)
A Single Dose (Part 1) and Multiple Dose (Part 2) Phase I, Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers

The purpose of this two-part study is to evaluate safety, tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in comparison to placebo in adult healthy volunteers.

This is a Phase I single-centre, double-blind, placebo-controlled, single and multiple dose study to evaluate safety, ocular tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in healthy volunteers for up to 15 days. After the single day dose (three times) on day 1 and the subsequent 7 (± 1) days wash-out period, a multidose phase with three times a day administration for 14 days will start

Primary objectives:

  • Part 1: To evaluate the safety and ocular tolerability of 0.5% and 2.5% cis-UCA eye drops and placebo for cis-UCA eye drops when administered on a randomized eye three times during a single day, assessed up to 7 (± 1) days following dosing in healthy volunteers
  • Part 2: To evaluate the safety and ocular tolerability of 0.5% and 2.5% cis-UCA eye drops and placebo for cis-UCA eye drops when administered on both eyes three times a day for 14 days, assessed up to 7 days following the last dosing in healthy volunteers

Secondary objectives:

  • To evaluate single dose pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops when administered on a randomized eye in adult healthy volunteers
  • To evaluate the pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops when administered on both eyes three times a day for 14 days in adult healthy volunteers

Healthy male or female volunteer, 18-65 years of age, with no history of significant eye disease or any current eye disease that would affect the pharmacokinetics of cis-UCA. Subjects without any treatment-emergent adverse events during Part 1 may continue to Part 2 of the study.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Dry Eye
  • Drug: cis-urocanic acid 0,5% eye drops
    one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
  • Drug: cis-urocanic acid 2.5% eye drops
    one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
  • Drug: Placebo for cis-UCA, eye drops
    one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
  • Experimental: Group 1: Cis-UCA 0.5% eye drops
    Intervention: Drug: cis-urocanic acid 0,5% eye drops
  • Experimental: Group 2: Cis-UCA 2.5% eye drops
    Intervention: Drug: cis-urocanic acid 2.5% eye drops
  • Placebo Comparator: Group 3: Placebo for cis-UCA, eye drops
    Intervention: Drug: Placebo for cis-UCA, eye drops
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
37
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Informed consent obtained prior to any screening procedure
  • Caucasian male or female subject
  • Age 18-65 y
  • Weight at least 45 kg
  • Corrected visual acuity > 20/25 in both eyes
  • Intraocular pressure < 21 mmHg, with a difference between eyes of < 4 mmHg
  • Ability to tolerate and self-administer vehicle eye drops
  • Normal slit lamp examination and dilated fundoscopic examination
  • Normal clinical laboratory profiles, defined as complete blood count, serum chemistry, and urinalysis values within the normal range
  • Willingness to abstain from concomitant use of ocular or systemic medication (excluding oral contraceptives, ibuprofen, paracetamol, calcium preparations and vitamins) from 2 weeks prior to the start of study dosing until study completion
  • Willingness to comply with study-related procedures
  • Negative urine pregnancy test (premenopausal female subject) at screening and use of adequate contraceptive measures throughout the study and 30 days after the last study medication dose
  • A premenopausal female subject should be either surgically sterile or using a reliable contraception method: intrauterine device; oral combination pill or hormonal contraception patch; or two of the following: intra-vaginal hormonal ring, oral contraceptive containing progestin only, spermicidal foam, condom, sterilization of male sexual partner (surgical vasectomy)
  • Subject with no current heterosexual relationship may be included according to the judgment of the Investigator
  • If menopause occurred 2 years ago at the minimum, no contraception is required for a female participant, nor pregnancy test
  • Reliable contraception for a male subject is concordant with above listed methods for females, as applicable

Exclusion Criteria:

  • History of ocular surgery, trauma, or chronic ocular disease
  • Current use of contact lenses or discontinuation of contact lens use within 2 weeks of the first dosing day
  • Any ocular abnormalities or ocular symptoms (defined as a non-zero score on assessment scales)
  • Use of ocular agents (including all types of eye drops) within the past month prior to the first dosing day or anticipated use of ocular agents during the study period
  • Use of systemic or inhaled nasal or pulmonary corticosteroids within the past month prior to the first dosing day
  • Use of systemic antihistamines within one week prior to the first dosing day
  • History or evidence of ocular infection, inflammation, blepharitis, or conjunctivitis within 2 months prior to the first dosing day; history of herpes simplex keratitis at any time
  • Current ocular allergy symptoms
  • Loss, donation, or removal of 400 ml or more of blood within 2 months prior to the first dosing day
  • Women who are pregnant or breastfeeding, or non-sterile or premenopausal women who refuse to use two proven methods of contraception during the study and for at least 30 days following the final dose of study drug
  • Participation in another clinical drug or device study within 2 months prior to the first dosing day
  • Current smoking
  • Current or history of drug or alcohol abuse
  • Known human immunodeficiency virus- or acquired immunodeficiency syndrome -related illness.
  • Allergy to cis-UCA, or any constituents of the cis-UCA eye drops (cis-urocanic acid, aqua, sodium chloride, polyvinyl alcohol, sodium hydroxide, and/or hydrochloric acid) or placebo for cis-UCA eye drops (aqua, sodium chloride, polyvinyl alcohol, sodium hydroxide, and/or hydrochloric acid)
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, would affect the subject's ability to follow study-related procedures, or may interfere with the interpretation of study results and, in the Investigator's opinion, would make the subject inappropriate for entry into this study.
  • Doubtful availability to complete the study
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Finland
 
NCT01476332
CL11001, 2011-004283-30
No
Laurantis Pharma, Ltd.
Laurantis Pharma, Ltd.
Kuopio University Hospital
Principal Investigator: Kai Kaarniranta, Professor Kuopio University Hospital, Department of Ophthalmology
Laurantis Pharma, Ltd.
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP